Microbot Medical (MBOT) said Wednesday that robotic endovascular procedures using its Liberty robotic system are feasible and significantly minimize radiation exposure, based on data from a study.
According to the study, successful robotic navigation was achieved in 20 cases, meeting its primary endpoint, the company said.
The study also resulted in a mean 92% reduction in radiation exposure.
The company said it may now move to building commercial capabilities and launch preparation, according to its President and CEO Harel Gadot.
Microbot Medical shares were up over 33% in premarket trading Wednesday.
Price: 1.86, Change: +0.47, Percent Change: +33.80
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。